New combo therapy could boost rectal cancer remission rates

NCT ID NCT07113275

First seen Feb 14, 2026 · Last updated May 10, 2026 · Updated 9 times

Summary

This study tests if adding immunotherapy to standard treatment (radiation and chemotherapy before surgery) helps more people with high-risk rectal cancer achieve complete remission. It also compares a shorter course of radiation to a longer one. About 435 adults with locally advanced rectal cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.